Brooks Laboratories Limited — Results, 07-03-2025: Reply to Clarification- Financial results

**Brooks Laboratories Limited Financial Overview**

Brooks Laboratories has reported consolidated revenue from operations of ₹2,051.51 crore for the quarter ending December 31, 2024, reflecting a slight decline from ₹2,174.66 crore in the same quarter last year, translating to a year-over-year decrease of 5.6%. The contraction is attributed to market pressures and competitive dynamics impacting sales. Total income for the quarter stands at ₹2,054.30 crore.

The company posted a net profit of ₹93.65 crore, compared to ₹57.76 crore for the corresponding quarter last year, marking a substantial increase driven primarily by stringent cost management and operational efficiencies. Earnings Per Share (EPS) for the quarter stands at ₹0.36, up from ₹0.23 in the previous year.

Operational costs rose minimally by 1.9%, with significant expenditures on materials and employee benefits being noteworthy. The cost of materials consumed was ₹1,216.82 crore, increasing marginally from the previous quarter, indicating potential upward price pressures.

On the balance sheet, total expenses were ₹1,960.65 crore, resulting in a healthy profit before tax of ₹93.65 crore. This suggests solid management of operational costs amid challenging market conditions.

Strategically, Brooks Laboratories appears focused on cost control and optimizing operational efficiencies. The recent slump in revenues could prompt management to explore new market segments or product lines, enhancing growth potential.

Given the solid profit growth despite revenue declines, along with effective cost management, a **buy** insight is suggested, as the company is well-positioned to capitalize on future opportunities while navigating current challenges.